Under the agreement's terms, Deinove will have a nine-month option period to assess the programme for further development by starting confirmatory and profiling work with the compounds included.
Redx will receive an option fee and payment on the exercise of the option, which are in proportion with the anti-infective programme at its current stage of development.
The Novel Bacterial Topoisomerase Inhibitor programme is mainly focused on the treatment of multi-drug resistant Gram negative bacteria.
"We are very pleased to have partnered our NBTI program with Deinove who are committed to the development of anti-infectives and whose team has a proven track record of bringing products to market. With their experience in this area, we hope that they can successfully progress our NBTI programme towards the clinic. We had previously indicated our commitment to progressing anti-infectives research through a collaboration in the near term and are delighted to be making this announcement on schedule," said Executive Chairman Iain Ross.
Shares in Redx Pharma were down 6.5% at
